QuidelOrtho Corporation (QDEL) Stock Positioned for Reweighting Towards Peers Amid Deleveraging
McIntyre Partnerships’ Q2 2026 investor letter discusses QuidelOrtho (NASDAQ:QDEL), a diagnostic testing company. The firm says QDEL could sell its POC division for about $1.5B to deleverage, leaving a RemainCo focused on legacy Ortho. It cites QDEL’s Aug 7 close at $12.28 and claims a 12x EV/EBITDA multiple could imply about $100/share.
How this was made
The 30-second read
Why it matters
The main tradable implication is a potential valuation re-rating if QDEL sells its POC division and the remaining RemainCo resembles the steadier Ortho business; however, the deal is described as rumored and not confirmed.
Market read
Traders may watch for confirmation of the POC sale process because it could change perceived leverage and the appropriate EV/EBITDA multiple.
What to watch
The article does not provide confirmation of binding negotiations, buyer identity, or deal closing conditions, which are key for valuation and risk reduction.
Background
The piece is an investor-letter discussion of QDEL’s capital structure and business segmentation, arguing a division sale could reduce volatility.
Ticker impact
McIntyre Partnerships says QuidelOrtho is looking to sell its POC division for about $1.5B to deleverage and reweight the stock toward peers.
Near-term sentiment could improve on any confirmation of the POC sale process, but the article provides no definitive deal terms or timing.
The text is an investor-letter thesis referencing an FT report and a rumored price, so it is directionally bullish but not a confirmed transaction.
Market effects
Could reinforce a broader diagnostics-sector narrative that portfolio simplification can compress valuation risk.
No clear regional catalyst beyond the company’s mention of prior China regulatory noise.
Limited, as the article centers on a single-company asset sale thesis.
Counterpoint
The POC sale may not clear on price, timing, or regulatory/operational constraints, leaving QDEL stuck with deleveraging uncertainty and continued estimate misses.
Key entities
- public_companyQuidelOrtho Corporation
NASDAQ-listed diagnostics company discussed as the largest portfolio holding and subject of a potential POC division sale.
- investment_fundMcIntyre Partnerships
Investment company whose Q2 2026 investor letter provides the thesis and valuation framework.
